Small cell lung cancer (SCLC) remains the deadliest thoracic neoplasm compared to other histotypes. The current introduction of frontline immunotherapy has resulted in an improvement in overall survival outcomes. However, the lack of predictive biomarkers of response and the lack of knowledge of subgroups defined by specific genomic signatures make these therapies' attempts still endowed with limited benefits.
In this Research Topic, we will deal with the most relevant topics of the modern clinical research, evaluating the new pathological sub-classification from which the concept of precision medicine derives. The major issues concerning frontline perspectives will be addressed to move on to the discussion on new therapeutic opportunities for refractory disease. The new therapies will be evaluated and discussed in view of the development of modern clinical research in order to outline what could be the most innovative and sustainable diagnostic therapeutic pathway also in this orphan disease.
Welcome topics include, but are not limited to, the following:
• From histological evaluation to transcription factors: a new way to classify SCLC
• The role of surgery in high-grade neuroendocrine cancer: indications for clinical practice
• The new frontiers of radiotherapy in the treatment of SCLC
• First-line treatment in SCLC
• Immunotherapy in SCLC
• Understanding the SCLC resistance to first-line treatment: therapeutic advances
• Lurbinectedin in SCLC
• Synthetic lethality and the role of PARP inhibitors in SCLC
• Harnessing DLL3 inhibitions: from old promises to new therapeutic horizons
• Epigenetic targets in the SCLC and its applications in clinical research
• Aurora kinase inhibitors in SCLC
Small cell lung cancer (SCLC) remains the deadliest thoracic neoplasm compared to other histotypes. The current introduction of frontline immunotherapy has resulted in an improvement in overall survival outcomes. However, the lack of predictive biomarkers of response and the lack of knowledge of subgroups defined by specific genomic signatures make these therapies' attempts still endowed with limited benefits.
In this Research Topic, we will deal with the most relevant topics of the modern clinical research, evaluating the new pathological sub-classification from which the concept of precision medicine derives. The major issues concerning frontline perspectives will be addressed to move on to the discussion on new therapeutic opportunities for refractory disease. The new therapies will be evaluated and discussed in view of the development of modern clinical research in order to outline what could be the most innovative and sustainable diagnostic therapeutic pathway also in this orphan disease.
Welcome topics include, but are not limited to, the following:
• From histological evaluation to transcription factors: a new way to classify SCLC
• The role of surgery in high-grade neuroendocrine cancer: indications for clinical practice
• The new frontiers of radiotherapy in the treatment of SCLC
• First-line treatment in SCLC
• Immunotherapy in SCLC
• Understanding the SCLC resistance to first-line treatment: therapeutic advances
• Lurbinectedin in SCLC
• Synthetic lethality and the role of PARP inhibitors in SCLC
• Harnessing DLL3 inhibitions: from old promises to new therapeutic horizons
• Epigenetic targets in the SCLC and its applications in clinical research
• Aurora kinase inhibitors in SCLC
